SCHEMBL23762997

SCHEMBL23762997

CC(C)(C)CC(C)(C(=O)OC1(c2ccccc2)CCCC1)C(C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ APOBEC3A P31941 3/20 0.38
▸ APOBEC3G Q9HC16 3/20 0.38
▸ AKR1C1 Q04828 1/20 0.37
▸ OPRM1 P35372 3/20 0.36
▸ OPRD1 P41143 3/20 0.36
▸ OPRK1 P41145 3/20 0.36
▸ DRD3 P35462 2/20 0.35
▸ PRCP P42785 1/20 0.34
▸ SIGMAR1 Q99720 1/20 0.34
▸ HDAC4 P56524 2/20 0.34
▸ ALDH1A1 P00352 3/20 0.34
▸ POLB P06746 2/20 0.34
▸ HTT P42858 2/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ HSD11B1 P28845 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24197480 0.99 APOBEC3A (0.37) APOBEC3AAPOBEC3GAKR1C1OPRM1OPRD1
SCHEMBL25513876 0.88 MAPT (0.33) OPRM1DRD3ALDH1A1SMN1; SMN2MEN1
SCHEMBL26152082 0.87 ADORA3 (0.34) OPRM1DRD3ALDH1A1SMN1; SMN2MEN1
SCHEMBL25469588 0.84 ELANE (0.39) DRD3ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL22168544 0.81 AKR1C1 (0.44) APOBEC3AAPOBEC3GAKR1C1OPRM1OPRD1
SCHEMBL13346700 0.80 OPRM1 (0.38) APOBEC3AAPOBEC3GAKR1C1OPRM1OPRD1
SCHEMBL25574954 0.80 AKR1C1 (0.43) APOBEC3AAPOBEC3GAKR1C1OPRM1OPRD1
SCHEMBL13346697 0.79 ADORA3 (0.39) APOBEC3AAPOBEC3GAKR1C1OPRM1OPRD1
SCHEMBL21012168 0.79 AKR1C1 (0.40) APOBEC3AAPOBEC3GAKR1C1OPRM1OPRD1
SCHEMBL13346710 0.79 OPRM1 (0.44) APOBEC3AAPOBEC3GAKR1C1OPRM1OPRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230161256-A1 SALT, ACID GENERATOR, RESIN, RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2023-05-25 — — US disclosed
US-20220011668-A1 SALT, ACID GENERATOR, RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2022-01-13 — — US disclosed
US-20210371377-A1 CARBOXYLATE, QUENCHER, RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2021-12-02 — — US disclosed
US-20210311392-A1 RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2021-10-07 — — US disclosed
US-20210286260-A1 RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2021-09-16 — — US disclosed
US-20210255545-A1 SALT, ACID GENERATOR, RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2021-08-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210371377-A1 CARBOXYLATE, QUENCHER, RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN CHRM1, CHRM2, FOXM1 APOBEC3A 1597/4885APOBEC3G 1472/4885AKR1C1 402/4885
US-20210255545-A1 SALT, ACID GENERATOR, RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN FGFR1, RER1, FGF1 APOBEC3A 4011/4885APOBEC3G 3790/4885AKR1C1 174/4885
US-20220011668-A1 SALT, ACID GENERATOR, RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN H1-0, H1-10, CHRM1 APOBEC3A 3372/4885APOBEC3G 3006/4885AKR1C1 299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback